GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (FRA:YBO0) » Definitions » Short-Term Debt

Tenax Therapeutics (FRA:YBO0) Short-Term Debt : €0.38 Mil (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Tenax Therapeutics Short-Term Debt?

Tenax Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.38 Mil.

Tenax Therapeutics's quarterly Short-Term Debt increased from Sep. 2023 (€0.16 Mil) to Dec. 2023 (€0.46 Mil) but then declined from Dec. 2023 (€0.46 Mil) to Mar. 2024 (€0.38 Mil).

Tenax Therapeutics's annual Short-Term Debt increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.59 Mil) but then declined from Dec. 2022 (€0.59 Mil) to Dec. 2023 (€0.46 Mil).


Tenax Therapeutics Short-Term Debt Historical Data

The historical data trend for Tenax Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics Short-Term Debt Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.10 - 0.59 0.46

Tenax Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.32 0.16 0.46 0.38

Tenax Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Tenax Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (FRA:YBO0) Business Description

Traded in Other Exchanges
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

Tenax Therapeutics (FRA:YBO0) Headlines

No Headlines